CN101068815B - 有效作为蛋白激酶抑制剂的内酰胺化合物 - Google Patents

有效作为蛋白激酶抑制剂的内酰胺化合物 Download PDF

Info

Publication number
CN101068815B
CN101068815B CN2005800414294A CN200580041429A CN101068815B CN 101068815 B CN101068815 B CN 101068815B CN 2005800414294 A CN2005800414294 A CN 2005800414294A CN 200580041429 A CN200580041429 A CN 200580041429A CN 101068815 B CN101068815 B CN 101068815B
Authority
CN
China
Prior art keywords
pyrimido
dihydro
amino
chloro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800414294A
Other languages
English (en)
Chinese (zh)
Other versions
CN101068815A (zh
Inventor
克里斯托弗·布莱克伯恩
克里斯托弗·F·克莱鲍恩
科特妮·A·卡立斯
娜塔利·A·戴尔斯
迈克·A·佩特恩
马修·斯蒂尔林
奥玛·G·斯维戴拉
加布里埃尔·S·外泽黑德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN101068815A publication Critical patent/CN101068815A/zh
Application granted granted Critical
Publication of CN101068815B publication Critical patent/CN101068815B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2005800414294A 2004-10-04 2005-10-03 有效作为蛋白激酶抑制剂的内酰胺化合物 Expired - Fee Related CN101068815B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61576104P 2004-10-04 2004-10-04
US60/615,761 2004-10-04
PCT/US2005/035458 WO2006041773A2 (en) 2004-10-04 2005-10-03 Lactam compounds useful as protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012102393383A Division CN102766142A (zh) 2004-10-04 2005-10-03 有效作为蛋白激酶抑制剂的内酰胺化合物

Publications (2)

Publication Number Publication Date
CN101068815A CN101068815A (zh) 2007-11-07
CN101068815B true CN101068815B (zh) 2012-09-05

Family

ID=35789256

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800414294A Expired - Fee Related CN101068815B (zh) 2004-10-04 2005-10-03 有效作为蛋白激酶抑制剂的内酰胺化合物
CN2012102393383A Pending CN102766142A (zh) 2004-10-04 2005-10-03 有效作为蛋白激酶抑制剂的内酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012102393383A Pending CN102766142A (zh) 2004-10-04 2005-10-03 有效作为蛋白激酶抑制剂的内酰胺化合物

Country Status (7)

Country Link
US (4) US7459448B2 (https=)
EP (2) EP2439207A1 (https=)
JP (2) JP5002460B2 (https=)
CN (2) CN101068815B (https=)
AU (1) AU2005294575B2 (https=)
CA (1) CA2582235A1 (https=)
WO (1) WO2006041773A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294575B2 (en) 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
US7985745B2 (en) * 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
EP2205603B1 (en) * 2007-09-28 2014-01-15 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
GB0800383D0 (en) * 2008-01-10 2008-02-20 Univ Strathclyde Weight reducing compounds
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US7998952B2 (en) * 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP5959537B2 (ja) * 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
CN102174016A (zh) * 2011-03-02 2011-09-07 宁波人健药业集团有限公司 一种制备7-氯-2,3,4,5-四氢-1h-1-苯并氮杂卓-2,5-二酮的方法
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
SG10201707409PA (en) 2013-03-13 2017-10-30 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
HRP20181272T1 (hr) 2013-11-13 2018-10-05 Vertex Pharmaceuticals Incorporated Postupci priprave inhibitora replikacije virusa influence
RS59144B1 (sr) 2013-11-13 2019-09-30 Vertex Pharma Inhibitori replikacije virusa influence
CN103601678B (zh) * 2013-11-21 2015-02-11 爱斯特（成都）医药技术有限公司 7-氯-1,2,3,4-四氢苯并[b]氮杂卓-5-酮的合成方法
CN106458868A (zh) 2014-04-17 2017-02-22 伊谬诺米特医疗有限公司 胍化合物及其用途
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2017070235A1 (en) * 2015-10-19 2017-04-27 Attenua, Inc. Antitussive compositions and methods
AU2017259654B2 (en) 2016-05-06 2020-02-27 Shanghai De Novo Pharmatech Co., Ltd. Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076424A1 (en) * 2003-02-27 2004-09-10 Abbott Laboratories Heterocyclic kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06172355A (ja) 1992-04-14 1994-06-21 Mect Corp ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5686445A (en) * 1993-07-29 1997-11-11 American Cyanamid Company Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
WO1997047624A1 (en) 1996-06-13 1997-12-18 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6723498B1 (en) 1999-06-30 2004-04-20 Millennium Pharmaceuticals, Inc. Chk1 and uses thereof
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
US6369222B1 (en) 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
US6686352B2 (en) * 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
WO2005007655A1 (en) 2003-07-21 2005-01-27 Pfizer Products Inc. Nicotine addiction reducing heteroaryl fused azapolycyclic compounds
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2540987T3 (es) * 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
AU2005294575B2 (en) * 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
US7998952B2 (en) * 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076424A1 (en) * 2003-02-27 2004-09-10 Abbott Laboratories Heterocyclic kinase inhibitors

Also Published As

Publication number Publication date
JP2012092143A (ja) 2012-05-17
AU2005294575A1 (en) 2006-04-20
EP2439207A1 (en) 2012-04-11
AU2005294575B2 (en) 2011-11-24
JP5002460B2 (ja) 2012-08-15
WO2006041773A2 (en) 2006-04-20
US20060100194A1 (en) 2006-05-11
US20110039820A1 (en) 2011-02-17
US7459448B2 (en) 2008-12-02
US20090105213A1 (en) 2009-04-23
CN102766142A (zh) 2012-11-07
JP2008515798A (ja) 2008-05-15
EP1799684A2 (en) 2007-06-27
WO2006041773A3 (en) 2006-05-18
CN101068815A (zh) 2007-11-07
CA2582235A1 (en) 2006-04-20
US20120178739A1 (en) 2012-07-12
US7935694B2 (en) 2011-05-03
EP1799684B1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
CN101068815B (zh) 有效作为蛋白激酶抑制剂的内酰胺化合物
ES2540987T3 (es) Métodos para preparar inhibidores de la aurora cinasa
JP2007537268A5 (https=)
ME00716B (me) Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze
CN101014603B (zh) 通过抑制极光激酶抑制有丝分裂的化合物和方法
EP1905773B1 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
HK1102500C (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
HK1102500B (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
HK1199254B (en) Process for the preparation of aurora kinase inhibitors
HK1114853B (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
HK1205102B (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120905

Termination date: 20131003